[1]
|
Mahoney, N.R., Liu, G.T., Menacker, S.J., Wilson, M.C., Hogarty, M.D. and Maris, J.M. (2006) Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass Lesions. American Journal of Ophthalmology, 142, 651-659. https://doi.org/10.1016/j.ajo.2006.05.047
|
[2]
|
Park, J.R., Eggert, A. and Caron, H. (2010) Neuroblastoma: Biology, Prognosis, and Treatment. Hematology/Oncology Clinics of North America, 24, 65-86.
https://doi.org/10.1016/j.hoc.2009.11.011
|
[3]
|
Matthay, K.K. (2013) Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption. Clinical Cancer Research, 19, 311-313.
https://doi.org/10.1158/1078-0432.CCR-12-3313
|
[4]
|
Wagner, L.M. and Danks, M.K. (2009) New Therapeutic Targets for the Treatment of High-Risk Neuroblastoma. Journal of Cellular Biochemistry, 107, 46-57.
https://doi.org/10.1002/jcb.22094
|
[5]
|
Pinto, N.R., Applebaum, M.A., Volchenboum, S.L., Matthay, K.K., London, W.B., Ambros, P.F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J.R., Valteau-Couanet, D., Pearson, A.D. and Cohn, S.L. (2015) Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 33, 3008-3017. https://doi.org/10.1200/JCO.2014.59.4648
|
[6]
|
Ishii, H., Iwatsuki, M., Ieta, K., Ohta, D., Haraguchi, N., Mimori, K. and Mori, M. (2008) Cancer Stem Cells and Chemoradiation Resistance. Cancer Science, 99, 1871-1877. https://doi.org/10.1111/j.1349-7006.2008.00914.x
|
[7]
|
Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C. and Dirks, P.B. (2009) Tumour-Initiating Cells: Challenges and Opportunities for Anticancer Drug Discovery. Nature Reviews Drug Discovery, 8, 806-823.
https://doi.org/10.1038/nrd2137
|
[8]
|
Fornari, C., Beccuti, M., Lanzardo, S., Conti, L., Balbo, G., Cavallo, F., Calogero, R.A. and Cordero, F. (2014) A Mathematical-Biological Joint Effort to Investigate the Tumor-Initiating Ability of Cancer Stem Cells. PLoS One, 9, e106193.
https://doi.org/10.1371/journal.pone.0106193
|
[9]
|
Dontu, G., Al-Hajj, M., Abdallah, W.M., Clarke, M.F. and Wicha, M.S. (2003) Stem Cells in Normal Breast Development and Breast Cancer. Cell Proliferation, 36, 59-72. https://doi.org/10.1046/j.1365-2184.36.s.1.6.x
|
[10]
|
O'Brien, C.A., Pollett, A., Gallinger, S. and Dick, J.E. (2007) A Human Colon Cancer Cell Capable of Initiating Tumour Growth in Immunodeficient Mice. Nature, 445, 106-110. https://doi.org/10.1038/nature05372
|
[11]
|
Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P. and Delattre, O. (2007) Mesenchymal Stem Cell Features of Ewing Tumors. Cancer Cell, 11, 421-429.
|
[12]
|
Ross, R.A. and Spengler, B.A. (2007) Human Neuroblastoma Stem Cells. Seminars in Cancer Biology, 17, 241-247.
|
[13]
|
Malik, F., Korkaya, H., Clouthier, S.G. and Wicha, M.S. (2012) Lin28 and HER2: Two Stem Cell Regulators Conspire to Drive Aggressive Breast Cancer. Cell Cycle, 11, 2780-2781. https://doi.org/10.4161/cc.21395
|
[14]
|
Viswanathan, S.R., Powers, J.T., Einhorn, W., Hoshida, Y., Ng, T.L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L.A., Lockhart, V.L., Shah, S.P., Tanwar, P.S., Mermel, C.H., Beroukhim, R., Azam, M., Teixeira, J., Meyerson, M., Hughes, T.P., Llovet, J.M., Radich, J., Mullighan, C.G., Golub, T.R., Sorensen, P.H. and Daley, G.Q. (2009) Lin28 Promotes Transformation and Is Associated with Advanced Human Malignancies. Nature Genetics, 41, 843-848. https://doi.org/10.1038/ng.392
|
[15]
|
Moss, E.G., Lee, R.C. and Ambros, V. (1997) The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. Elegans and Is Regulated by the Lin-4 RNA. Cell, 88, 637-646.
|
[16]
|
Wang, T., Wang, G., Hao, D., Liu, X., Wang, D., Ning, N. and Li, X. (2015) Aberrant Regulation of the LIN28A/LIN28B and Let-7 Loop in Human Malignant Tumors and Its Effects on the Hallmarks of Cancer. Molecular Cancer, 14, 125.
https://doi.org/10.1186/s12943-015-0402-5
|
[17]
|
King, C.E., Cuatrecasas, M., Castells, A., Sepulveda, A.R., Lee, J.S. and Rustgi, A.K. (2011) LIN28B Promotes Colon Cancer Progression and Metastasis. Cancer Research, 71, 4260-4268. https://doi.org/10.1158/0008-5472.can-10-4637
|
[18]
|
Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S. and Sarkar, F.H. (2010) Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells. PLoS ONE, 5, e12445.
https://doi.org/10.1371/journal.pone.0012445
|
[19]
|
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J. and Song, E. (2007) Let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells. Cell, 131, 1109-1123.
|
[20]
|
Meirelles, K., Benedict, L.A., Dombkowski, D., Pepin, D., Preffer, F.I., Teixeira, J., Tanwar, P.S., Young, R.H., MacLaughlin, D.T., Donahoe, P.K. and Wei, X. (2012) Human Ovarian Cancer Stem/Progenitor Cells Are Stimulated by Doxorubicin But Inhibited by Mullerian Inhibiting Substance. Proceedings of the National Academy of Sciences of the United States, 109, 2358-2363.
https://doi.org/10.1073/pnas.1120733109
|
[21]
|
Molenaar, J.J., Domingo-Fernandez, R., Ebus, M.E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L.J., van Nes, J., Broekmans, M., Haneveld, F., Volckmann, R., Bray, I., Heukamp, L., Sprussel, A., Thor, T., Kieckbusch, K., Klein-Hitpass, L., Fischer, M., Vandesompele, J., Schramm, A., van Noesel, M.M., Varesio, L., Speleman, F., Eggert, A., Stallings, R.L., Caron, H.N., Versteeg, R. and Schulte, J.H. (2012) LIN28B Induces Neuroblastoma and Enhances MYCN Levels via Let-7 Suppression. Nature Genetics, 44, 1199-1206.
https://doi.org/10.1038/ng.2436
|
[22]
|
Samal, K., Zhao, P., Kendzicky, A., Yco, L.P., McClung, H., Gerner, E., Burns, M., Bachmann, A.S. and Sholler, G. (2013) AMXT-1501, a Novel Polyamine Transport Inhibitor, Synergizes with DFMO in Inhibiting Neuroblastoma Cell Proliferation by Targeting Both Ornithine Decarboxylase and Polyamine Transport. International Journal of Cancer, 133, 1323-1333. https://doi.org/10.1002/ijc.28139
|
[23]
|
Lange, I., Geerts, D., Feith, D.J., Mocz, G., Koster, J. and Bachmann, A.S. (2014) Novel Interaction of Ornithine Decarboxylase with Sepiapterin Reductase Regulates Neuroblastoma Cell Proliferation. Journal of Molecular Biology, 426, 332-346.
|
[24]
|
Saulnier Sholler, G.L., Gerner, E.W., Bergendahl, G., MacArthur, R.B., VanderWerff, A., Ashikaga, T., Bond, J.P., Ferguson, W., Roberts, W., Wada, R.K., Eslin, D., Kraveka, J.M., Kaplan, J., Mitchell, D., Parikh, N.S., Neville, K., Sender, L., Higgins, T., Kawakita, M., Hiramatsu, K., Moriya, S.S. and Bachmann, A.S. (2015) A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS ONE, 10, e0127246.
https://doi.org/10.1371/journal.pone.0127246
|
[25]
|
Lozier, A.M., Rich, M.E., Grawe, A.P., Peck, A.S., Zhao, P., Chang, A.T., Bond, J.P. and Sholler, G.S. (2015) Targeting Ornithine Decarboxylase Reverses the LIN28/Let-7 Axis and Inhibits Glycolytic Metabolism in Neuroblastoma. Oncotarget, 6, 196-206.
|
[26]
|
Cusack, J.C., Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J. and Baldwin, A.S. (2001) Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341: Implications for Systemic Nuclear Factor-kappaB Inhibition. Cancer Research, 61, 3535-3540.
|
[27]
|
Kane, R.C., Bross, P.F., Farrell, A.T. and Pazdur, R. (2003) Velcade: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. Oncologist, 8, 508-513. https://doi.org/10.1634/theoncologist.8-6-508
|
[28]
|
Chen, D., Frezza, M., Schmitt, S., Kanwar, J. and Dou, Q.P. (2011) Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Current Cancer Drug Targets, 11, 239-253.
https://doi.org/10.2174/156800911794519752
|
[29]
|
Iliopoulos, D., Hirsch, H.A. and Struhl, K. (2009) An Epigenetic Switch Involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation. Cell, 139, 693-706.
|
[30]
|
Michaelis, M., Fichtner, I., Behrens, D., Haider, W., Rothweiler, F., Mack, A., Cinatl, J., Doerr, H.W. and Cinatl, J. (2006) Anti-Cancer Effects of Bortezomib against Chemoresistant Neuroblastoma Cell Lines in Vitro and in Vivo. International Journal of Oncology, 28, 439-446. https://doi.org/10.3892/ijo.28.2.439
|
[31]
|
Combaret, V., Boyault, S., Iacono, I., Brejon, S., Rousseau, R. and Puisieux, A. (2008) Effect of Bortezomib on Human Neuroblastoma: Analysis of Molecular Mechanisms Involved in Cytotoxicity. Molecular Cancer, 7, 50.
https://doi.org/10.1186/1476-4598-7-50
|
[32]
|
Brignole, C., Marimpietri, D., Pastorino, F., Nico, B., Di Paolo, D., Cioni, M., Piccardi, F., Cilli, M., Pezzolo, A., Corrias, M.V., Pistoia, V., Ribatti, D., Pagnan, G. and Ponzoni, M. (2006) Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. Journal of the National Cancer Institute, 98, 1142-1157. https://doi.org/10.1093/jnci/djj309
|
[33]
|
Berenson, J.R., Matous, J., Swift, R.A., Mapes, R., Morrison, B. and Yeh, H.S. (2007) A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research, 13, 1762-1768. https://doi.org/10.1158/1078-0432.ccr-06-1812
|
[34]
|
Valentiner, U., Haane, C., Nehmann, N. and Schumacher, U. (2009) Effects of Bortezomib on Human Neuroblastoma Cells in Vitro and in a Metastatic Xenograft Model. Anticancer Research, 29, 1219-1225.
|
[35]
|
Armstrong, M.B., Schumacher, K.R., Mody, R., Yanik, G.A., Opipari, A.W. and Castle, V.P. (2008) Bortezomib as a Therapeutic Candidate for Neuroblastoma. Journal of Experimental Therapeutics & Oncology, 7, 135-145.
|
[36]
|
Brodeur, G.M. (2003) Neuroblastoma: Biological Insights into a Clinical Enigma. Nature Reviews Cancer, 3, 203-216. https://doi.org/10.1038/nrc1014
|
[37]
|
Huang, M. and Weiss, W.A. (2013) Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine, 3, a014415.
https://doi.org/10.1101/cshperspect.a014415
|
[38]
|
Powers, J.T., Tsanov, K.M., Pearson, D.S., Roels, F., Spina, C.S., Ebright, R., Seligson, M., de Soysa, Y., Cahan, P., Theissen, J., Tu, H.C., Han, A., Kurek, K.C., LaPier, G.S., Osborne, J.K., Ross, S.J., Cesana, M., Collins, J.J., Berthold, F. and Daley, G.Q. (2016) Multiple Mechanisms Disrupt the Let-7 microRNA Family in Neuroblastoma. Nature, 535, 246-251. https://doi.org/10.1038/nature18632
|
[39]
|
Diskin, S.J., Capasso, M., Schnepp, R.W., Cole, K.A., Attiyeh, E.F., Hou, C., Diamond, M., Carpenter, E.L., Winter, C., Lee, H., Jagannathan, J., Latorre, V., Iolascon, A., Hakonarson, H., Devoto, M. and Maris, J.M. (2012) Common Variation at 6q16 within HACE1 and LIN28B Influences Susceptibility to Neuroblastoma. Nature Genetics, 44, 1126-1130. https://doi.org/10.1038/ng.2387
|
[40]
|
Paz, E.A., LaFleur, B. and Gerner, E.W. (2014) Polyamines Are Oncometabolites That Regulate the LIN28/Let-7 Pathway in Colorectal Cancer Cells. Molecular Carcinogenesis, 53, E96-E106. https://doi.org/10.1002/mc.22051
|
[41]
|
Facchini, A., Borzi, R.M., Marcu, K.B., Stefanelli, C., Olivotto, E., Goldring, M.B., Facchini, A. and Flamigni, F. (2005) Polyamine Depletion Inhibits NF-kappaB Binding to DNA and Interleukin-8 Production in Human Chondrocytes Stimulated by Tumor Necrosis Factor-Alpha. Journal of Cellular Physiology, 204, 956-963.
https://doi.org/10.1002/jcp.20368
|
[42]
|
Naugler, W.E. and Karin, M. (2008) NF-kappaB and Cancer-Identifying Targets and Mechanisms. Current Opinion in Genetics & Development, 18, 19-26.
|
[43]
|
Brown, R.E., Tan, D., Taylor, J.S., Miller, M., Prichard, J.W. and Kott, M.M. (2007) Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in High Risk Neuro-Blastoma, with Cell Cycle and Protein Analyte Correlates. Annals of Clinical & Laboratory Science, 37, 141-147.
|
[44]
|
Zhi, Y., Lu, H., Duan, Y., Sun, W., Guan, G., Dong, Q. and Yang, C. (2015) Involvement of the Nuclear Factor-kappaB Signaling Pathway in the Regulation of CXC Chemokine Receptor-4 Expression in Neuroblastoma Cells Induced by Tumor Necrosis Factor-Alpha. International Journal of Molecular Medicine, 35, 349-357.
|
[45]
|
Zhu, H., Shyh-Chang, N., Segre, A.V., Shinoda, G., Shah, S.P., Einhorn, W.S., Takeuchi, A., Engreitz, J.M., Hagan, J.P., Kharas, M.G., Urbach, A., Thornton, J.E., Triboulet, R., Gregory, R.I., Consortium, D., Investigators, M., Altshuler, D. and Daley, G.Q. (2011) The Lin28/Let-7 Axis Regulates Glucose Metabolism. Cell, 147, 81-94.
|
[46]
|
D’Angelo, R.C. and Wicha, M.S. (2010) Stem Cells in Normal Development and Cancer. Progress in Molecular Biology and Translational Science, 95, 113-158.
|
[47]
|
Warburg, O. (1956) On the Origin of Cancer Cells. Science, 123, 309-314.
https://doi.org/10.1126/science.123.3191.309
|
[48]
|
Kushner, B.H., Yeung, H.W., Larson, S.M., Kramer, K. and Cheung, N.K. (2001) Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients. Journal of Clinical Oncology, 19, 3397-405.
https://doi.org/10.1200/jco.2001.19.14.3397
|
[49]
|
Denko, N.C. (2008) Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour. Nature Reviews Cancer, 8, 705-713. https://doi.org/10.1038/nrc2468
|